Vertaling van "our medicines for people in both developing " (Nederlands → Frans) :

How can we provide or improve access to our medicines, for people in both developing and developed nations?
Comment donner ou améliorer l’accès à nos médicaments, autant dans les pays développés qu’en voie de développement ?

Delivering innovation, growth and productivity The success of Novartis is driven by a commitment to three strategic priorities: (1) extending our lead in innovation through the research and development of differentiated new medicines, vaccines and diagnostics; (2) accelerating growth across all divisions by broadening our product portfolios with new launches and increasing our presence in new markets; and (3) improving profitability through productivity by streamlining and simplifying our processes.
Promouvoir l'innovation, la croissance et la productivité Le succès de Novartis est porté par son engagement envers trois priorités stratégiques: Augmenter notre avance dans l’innovation en recherchant et développant de nouveaux médicaments, vaccins et diagnostics différenciés, 2) accélérer notre croissance dans toutes les divisions en élargissant notre portefeuille par le lancement de nouveaux de produits et en accroissant notre présence dans de nouveaux marchés et 3) améliorer notre profitabilité par le biais de la productivité en rationalisant et en simplifiant nos processus.

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.
The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.

The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.
The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.